Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Study finds ABVD standard chemotherapy effective for Hodgkin's lymphoma

A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease, according to a first-of-its-kind randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Stereotactic radiation effective for trigeminal neuralgia

Stereotactic radiation is an effective, long-term treatment for trigeminal neuralgia: a painful condition that occurs with increased frequency in patients with multiple sclerosis (MS). Radiation is noninvasive and has less negative side effects than other treatments, according to the longest follow-up in a study of its kind presented October 31, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Routine prostate cancer screening reduces metastasis risk

Men treated for prostate cancer who were diagnosed after the start of routine screening had a significantly reduced risk of the disease spreading to other parts of the body (metastases) within 10 years of treatment, compared to men who were treated prior to the use of routine screening, according to the first study-of-its-kind presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

CINJ researcher receives Clinical/Basic Science Research Award

Amar Rewari, MD, MBA, a researcher from The Cancer Institute of New Jersey (CINJ), has been chosen to receive the Clinical Award in Clinical/Basic Science Research at the 52nd Annual Meeting of The American Society for Radiation Oncology (ASTRO) in San Diego next month. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

26 Oct 2010

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the presentation of Phase II data from Hodgkin Lymphoma patients treated in the 1st Simon Stage cohort of the ongoing SAPHIRE study with resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany.

26 Oct 2010

Short course of radiation before surgery reduces rectal cancer recurrence: Study

Patients with cancer found at the end of the large intestine called the rectum who receive one week of radiation therapy before surgery have a 50 percent reduction in chance that their cancer will return after 10 years, according to a large, randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that new data on TRC105 and TRC102 will be presented at the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

26 Oct 2010

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

The John Theurer Cancer Center at Hackensack University Medical Center unveiled a new $130-million, 155,000-square-foot comprehensive cancer facility that will enhance the cancer center's ability to deliver multidisciplinary extraordinary care, best-in-class clinical quality, and cutting-edge research. The doors will open for patients in January 2011.

26 Oct 2010

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance of survival compared to patients who do not receive radiation, according to interim results of the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Chemoradiotherapy can reduce bladder cancer recurrence

A major bladder cancer trial, funded by Cancer Research UK, has shown that adding two commonly used chemotherapy drugs to traditional radiotherapy can reduce the chance of a patient's tumour coming back by a third.

26 Oct 2010

Aspirin reduces risk of death from prostate cancer

Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.

26 Oct 2010

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.

26 Oct 2010

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Men with prostate cancer treated with a specialized type of radiation called intensity modulated radiation therapy (IMRT) have fewer gastrointestinal complications compared to patients treated with conventional three-dimensional conformal radiotherapy (3D-CRT), according to a study presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Combination of chemotherapy and radiation improves control of cancer within bladder

Adding chemotherapy to radiation therapy for muscle invasive bladder cancer allows 67 percent of people to be free of disease in their bladders two years after treatment. This compares to 54 percent of people who receive radiation alone, according to the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

UMC of Göttingen purchases BSD-500 Hyperthermia System

BSD Medical Corporation announced today that the University Medical Center (UMC) of Göttingen, Germany, has purchased a BSD-500 Hyperthermia System (BSD-500). UMC was established in 1732 and is a center of scientific excellence in Europe and the most prominent medical center in Lower Saxony, Germany.

25 Oct 2010

FDA approves Roche's real-time PCR COBAS TaqMan HCV Test, v2.0

Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.

25 Oct 2010

First implantation of Neo-Urinary Conduit in bladder cancer patient performed at University of Chicago

Tengion, Inc., a leader in regenerative medicine, announced today that surgeons at the University of Chicago have implanted its Neo-Urinary Conduit™ in the first patient as part of the ongoing clinical trial evaluating the Company's lead product candidate in bladder cancer patients requiring a urinary diversion following bladder removal.

25 Oct 2010

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that brentuximab vedotin (SGN-35) will be featured in three poster presentations at the 8th International Symposium on Hodgkin Lymphoma (ISHL) being held October 23-26, 2010 in Cologne, Germany.

25 Oct 2010

O2h to provide ADME services to Sentinel Oncology under new extended contract

Executives from Sentinel Oncology Limited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) to extend the number of FTEs working for Sentinel Oncology. Under this new contract, O2h will also provide ADME services to Sentinel Oncology.

25 Oct 2010

NIH awards $3.9M for Fanconi anemia research

The National Institutes of Health has awarded a three-year, $3.9 million grant to Children's Hospital Boston researchers and their colleagues to develop a therapy to treat Fanconi anemia, a fatal genetic blood disease.

25 Oct 2010

Oncology News and Research

Further Reading

Study finds ABVD standard chemotherapy effective for Hodgkin's lymphoma

Stereotactic radiation effective for trigeminal neuralgia

Routine prostate cancer screening reduces metastasis risk

CINJ researcher receives Clinical/Basic Science Research Award

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

Short course of radiation before surgery reduces rectal cancer recurrence: Study

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Chemoradiotherapy can reduce bladder cancer recurrence

Aspirin reduces risk of death from prostate cancer

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Combination of chemotherapy and radiation improves control of cancer within bladder

UMC of Göttingen purchases BSD-500 Hyperthermia System

FDA approves Roche's real-time PCR COBAS TaqMan HCV Test, v2.0

First implantation of Neo-Urinary Conduit in bladder cancer patient performed at University of Chicago

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

O2h to provide ADME services to Sentinel Oncology under new extended contract

NIH awards $3.9M for Fanconi anemia research

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News